Hims & Hers Health (HIMS) climbed roughly 3% in Monday trading as investors positioned ahead of the company’s first-quarter 2026 earnings report, which is scheduled for after the market close on May 11, 2026. With the reporting date approaching, incremental buying pressure can emerge as traders anticipate updates on demand trends, subscriber growth, and the company’s weight-loss and broader multi-specialty telehealth initiatives.

The company has already communicated the Q1 reporting date and an upcoming management appearance at an investor conference in early June, keeping attention on near-term catalysts. Separately, late-April analyst commentary and price-target resets have been supportive of sentiment, reinforcing the view that the stock’s recent recovery could continue into the earnings event if key metrics remain strong.

Into the May 11 report, the market focus is likely to center on subscriber additions, revenue growth, and any commentary around the economics of weight-loss offerings versus legacy categories. Investors will also scrutinize any changes to 2026 outlook and signals on product mix, as those variables can drive volatility around the earnings release.